Prevention of sudden cardiac death in patients with chronic kidney disease

BMC Nephrology

Jacek Rysz²  Jolanta Małyszko¹  Dariusz Kozłowski³  Maciej Banach⁴  Anna Gluba²  Beata Franczyk-Skóra² 

[1] Department of Nephrology and Transplantology, Medical University, Bialystok, Poland;Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, Lodz, Poland;Department of Cardiology and Electrotherapy, Second Chair of Cardiology, Medical University of Gdansk, Gdansk, Poland;Department of Hypertension, WAM University Hospital in Lodz, Medical University of Lodz, Zeromskiego 113, Lodz, 90-549, Poland

关键词: Sudden cardiac death;    Renal failure;    Chronic kidney disease;    Arrhythmias;   

Others  :  1083485
DOI  :  10.1186/1471-2369-13-162

 received in 2012-07-08, accepted in 2012-11-27,  发布年份 2012

【 摘 要 】

Cardiovascular deaths account for about 40% of all deaths of patients with chronic kidney disease (CKD), particularly those on dialysis, while sudden cardiac death (SCD) might be responsible for as many as 60% of SCD in patients undergoing dialysis. Studies have demonstrated a number of factors occurring in hemodialysis (HD) that could lead to cardiac arrhythmias. Patients with CKD undergoing HD are at high risk of ventricular arrhythmia and SCD since changes associated with renal failure and hemodialysis-related disorders overlap. Antiarrhythmic therapy is much more difficult in patients with CKD, but the general principles are similar to those in patients with normal renal function - at first, the cause of arrhythmias should be found and eliminated. Also the choice of therapy is narrowed due to the altered pharmacokinetics of many drugs resulting from renal failure, neurotoxicity of certain drugs and their complex interactions. Cardiac pacing in elderly patients is a common method of treatment. Assessment of patients’ prognosis is important when deciding whether to implant complex devices. There are reports concerning greater risk of surgical complications, which depends also on the extent of the surgical site. The decision concerning implantation of a pacing system in patients with CKD should be made on the basis of individual assessment of the patient.

【 授权许可】

   
2012 Franczyk-Skora et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]European Cardiovascular Disease Statistics [http://www.ehnheart.org/cvd-statistics.html] webcite 2012.
• [2]Allender S, Scarborough P, Peto V, Rayner M, Leal J, Luengo-Fernandez R, Alastair G: European cardiovascular disease statistics. [http:/ / www.herzstiftung.ch/ uploads/ media/ European_cardiovascular_disease_sta tistics_2008.pdf] webcite
• [3]Athyros VG, Hatzitolios AI, Karagiannis A, et al.: IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. Arch Med Sci 2011, 7:984-992.
• [4]USRDS Annual Data Report. Cardiovascular special studies [http://www.usrds.org/2004/pdf/09_cardio_04.pdf] webcite
• [5]ERA-EDTA Registry: Annual Report. [http://www.era-edta-reg.org/files/annualreports/pdf/AnnRep2010.pdf] webcite 2010.
• [6]Puka J, Rutkowski B, Lichodziejewska-Niemierko M, et al.: Report on renal replacement therapy in Poland in 2003. Gdańsk: MAK-media; 2004. (in Polish)
• [7]Gluba A, Mikhailidis DP, Lip GY, Hannam S, Rysz J, Banach M: Metabolic syndrome and renal disease. Int J Cardiol 2012.
• [8]Malyszko J, Bachorzewska-Gajewska H, Malyszko J, Iaina-Levin N, Kobus G, Dobrzycki S: Markers of kidney function in the elderly in relation to the new CKD-EPI formula for estimation of glomerular filtration rate. Arch Med Sci 2011, 7:658-664.
• [9]Rysz J, Aronow WS, Stolarek RS, Hannam S, Mikhailidis DP, Banach M: Nephroprotective and clinical potential of statins in dialyzed patients. Expert Opin Ther Targets 2009, 13:541-550.
• [10]Park SH, Stenvinkel P, Lindholm B: Cardiovascular biomarkers in chronic kidney disease. J Ren Nutr 2012, 22(1):120-127.
• [11]Anavekar NS, Mc Murmay JJ, Velazquez EJ, et al.: Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Eng J Med 2004, 351:1285-1295.
• [12]Szczech LA, Best PJ, Crowley E, et al.: Outcomes of patients with chronic renal insufficiency in the bypass angioplasty revascularization investigation. Circulation 2002, 105:2253-2258.
• [13]Elsayed EF, Tighiouart H, Griffith J, Kurth T, et al.: Cardiovascular disease and subsequent kidney disease. Arch Intern Med 2007, 167(11):1130-1136.
• [14]Fredman BI: Chronic Kidney disease: cause and consequence of cardiovascular disease. Arch Intern Med 2007, 167(11):1113-1115.
• [15]Shamseddin MK, Parfrey PS: Sudden cardiac death in chronic kidney disease: epidemiology and prevention. Nat Rev Nephrol 2011, 7(3):145-154.
• [16]Naruse Y, Tada H, Sekiguchi Y, Machino T, Ozawa M, Yamasaki H, Igarashi M, Kuroki K, Itoh Y, Murakoshi N, Yamaguchi I, Aonuma K: Concomitant chronic kidney disease increases the recurrence of atrial fibrillation after catheter ablation of atrial fibrillation: a mid-term follow-up. Heart Rhythm 2011, 8(3):335-341.
• [17]Couser WG, Riella MC: World Kidney Day 2011: Protect your kidneys, save your heart. Arch Med Sci 2011, 7:1-4.
• [18]Aronow WS, Banach M: Ten most important things to learn from the ACCF/AHA 2011 expert consensus document on hypertension in the elderly. Blood Press 2012, 21(1):3-5.
• [19]Yildirir A, Batur MK, Oto A: Hypertension and arrhythmia: blood pressure control and beyond. Europace 2002, 4:175-182.
• [20]Morin DP, Oikarinen L, Viitasalo M, Toivonen L, Nieminen MS, Kjeldsen SE, Dahlöf B, John M, Devereux RB, Okin PM: QRS duration predicts sudden cardiac death in hypertensive patients undergoing intensive medical therapy: the LIFE study. Eur Heart J 2009, 30(23):2908-2914.
• [21]Herzog CA: Cardiac arrest in dialysis patients: approaches to alter an abysmal outcome. Kidney Int 2003, 63(Suppl. 84):197-200.
• [22]Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK: Association of elevated serum PO4, Ca × PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J. Am. Soc. Nephrol 2001, 12:2131-2138.
• [23]Herzog CA, Strief J, Collins AJ, Gilbertson DT: Cause-specific mortality of dialysis patients after coronary revascularization: why don’t dialysis patients have better survival after coronary intervention? Nephrol Dial Transplant 2008, 23:2629-2633.
• [24]Pun PH, Smarz TR, Honeycutt EF, Shaw LK, Al-Khatib SM, Middleton JP: Chronic kidney disease is associated with increased risk of sudden cardiac death among patients with coronary artery disease. Kidney Int 2009, 76:652-658.
• [25]Malyszko J, Zbroch E, Malyszko J, Mysliwiec M, Iaina A: The cardio-renal-anaemia syndrome predicts survival in peritoneally dialyzed patients. Arch Med Sci 2010, 6:539-544.
• [26]Karnik JA, Young BS, Lew NL, Herget M, Dubinsky C, Lazarus JM, Chertow GM: Cardiac arrest and sudden death in dialysis units. Kidney Int 2001, 60:350-357.
• [27]Bleyer AJ, Hartman J, Brannon PC, Reeves-Daniel A, Satko SG, Russell G: Characteristics of sudden death in hemodialysis patients. Kidney Int 2006, 69:2268-2273.
• [28]Muller J, Kaufmann P, Luepker R, et al.: Mechanisms precipitating acute cardiac arrest: review and recommendations of an NHLBI workshop. Circulation 1997, 96:3233-3239.
• [29]Wu VC, Huang JW, Wu MS, Chin CY, Chiang FT, Liu YB, Wu KD: The effect of iron stores on corrected QT dispersion in patients undergoing peritoneal dialysis. Am J Kidney Dis 2004, 44:720-728.
• [30]Koc Y, Unsal A, Kayabasi H, Oztekin E, Sakaci T, Ahbap E, Yilmaz M, Akgun AO: Impact of volume status on blood pressure and left ventricle structure in patients undergoing chronic hemodialysis. Ren Fail 2011, 33(4):377-381.
• [31]Stewart GA, Gansevoort RT, Mark PB, Rooney E, McDonagh TA, Dargie HJ, Stuart R, Rodger C, Jardine AG: Electrocardiographic abnormalities and uremic cardiomyopathy. Kidney Int 2005, 67:217-226.
• [32]Amann K, Kronenberg G, Gehlen F, Wessels S, Orth S, Münter K, Ehmke H, Mall G, Ritz E: Cardiac remodeling in experimental renal failure - an immunohistochemical study. Nephrol. DialTransplant 1998, 13:1958-1966.
• [33]Covic A, Diaconita M, Gusbeth-Tatomir P, Covic M, Botezan A, Ungureanu G, Goldsmith DJ: Hemodialysis increases QTc interval but not QTc dispersion in ESRD patients without manifest cardiac disease. Nephrol. Dial Transplant 2002, 17:2170-2177.
• [34]Beaubien ER, Pylypchuk GB, Akhtar J, Biem HJ: Value of corrected QT interval dispersion in identifying patients initiating dialysis at increased risk of total and cardiovascular mortality. Am J Kidney Dis 2002, 39:834-842.
• [35]Cicero AF, Ertek S: Preclinical and clinical evidence of nephro- and cardiovascular protective effects of glycosaminoglycans. Arch Med Sci 2010, 6(4):469-477.
• [36]Rysz J, Banach M, Stolarek RA, Mikhailidis DP, Cialkowska-Rysz A, Pokoca L, Piechota M, Baj Z: Serum metalloproteinases MMP-2, MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in patients on hemodialysis. Int Urol Nephrol 2011, 43(2):491-498.
• [37]Rysz J, Banach M, Cialkowska-Rysz A, Stolarek R, Barylski M, Drozdz J, Okonski P: Blood serum levels of IL-2, IL-6, IL-8, TNF-alpha and IL-1beta in patients on maintenance hemodialysis. Cell Mol Immunol 2006, 3(2):151-154.
• [38]Ravani P, et al.: Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 2005, 16:2449-2455.
• [39]Rysz J, Majewska E, Stolarek RA, Banach M, Ciałkowska-Rysz A, Baj Z: Increased levels of soluble TNF-alpha receptors and cellular adhesion molecules in patients undergoing bioincompatible hemodialysis. Am J Nephrol 2006, 26:437-444.
• [40]Shamseddin MK, Parfrey PS: Mechanisms of the cardiorenal syndromes. Nat Rev Nephrol 2009, 5:641-649.
• [41]Mallamaci F, Zoccali C, Tripepi G, Fermo I, Benedetto FA, Cataliotti A, Bellanuova I, Malatino LS, Soldarini A, CREED Investigators: Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 2002, 61:609-614.
• [42]Fadel FI, Abdel Rahman AMO, Farouk M, et al.: Plasma neutrophil gelatinase-associated lipocalin as an early biomarker for prediction of acute kidney injury after cardio-pulmonary bypass in pediatric cardiac surgery. Arch Med Sci 2012, 8:250-255.
• [43]Pamuccio V, Tripepi R, Tripepi G, Mallamaci F, Benedetto FA, Cataliotti A, Bellanuova I, Giacone G, Malatino LS, Zoccali C: Heart valve calcifications survival and cardiovascular risk in hemodialysis patients. Am J Kidney Dis 2004, 43:479-484.
• [44]Kitano Y, Kasuga H, Watanabe M, Takahashi H, Ibuki K, Kawade Y, Yasuda K, Iwashima S, Toriyama T, Matuo S, Kawahara H: Severe coronary stenosis is an important factor for induction and lengthy persistence of ventricular arrhythmias during and after hemodialysis. Am J Kidney Dis 2004, 44:328-336.
• [45]Parekh RS, Plantinga LC, Kao WH, Meoni LA, Jaar BG, Fink NE, Powe NR, Coresh J, Klag MJ: The association of sudden cardiac death with inflammation and other traditional risk factors. Kidney Int 2008, 74:1335-1342.
• [46]Kowalczyk M, Banach M, Rysz J: Ferumoxytol: a new era of iron deficiency anemia treatment for patients with chronic kidney disease. J Nephrol 2011, 24(6):717-722.
• [47]Kanbay M, Solak Y, Covic A, Goldsmith D: Sudden cardiac death in patients with chronic kidney disease: prevention is the sine qua non. Kidney Blood Press Res 2011, 34(4):269-276.
• [48]Russo D, Corrao S, Miranda I, Ruocco C, Manzi S, Elefante R, Brancaccio D, Cozzolino M, Biondi ML, Andreucci VE: Progression of coronary artery calcification in predialysis patients. Am J Nephrol 2007, 27(2):152-158.
• [49]Alan C, Kocoglu H, Altıntas R, Alıcı B, Ersay AR: Protective effect of decorin on acute ischaemia-reperfusion injury in the rat kidney. Arch Med Sci 2011, 7:211-216.
• [50]Sharma R, Gaze DC, Pellerin D, Mehta RL, Gregson H, Streather CP, Collinson PO, Brecker SJ: Ischemia-modified albumin predicts mortality in ESRD. Am J Kidney Dis 2006, 47:493-502.
• [51]Nishimura M, Tsukamoto K, Hasebe N, Tamaki N, Kikuchi K, Ono T: Prediction of cardiac death in hemodialysis patients by myocardial fatty acid imaging. J Am Coll Cardiol 2008, 51:139-145.
• [52]Johansson M, Gao SA, Friberg P, Annerstedt M, Bergström G, Carlström J, Ivarsson T, Jensen G, Ljungman S, Mathillas O, Nielsen FD, Strömbom U: Reduced baroreflex effectiveness index in hypertensive patients with chronic renal failure. Am J Hypertens 2005, 18:995-1000.
• [53]Johansson M, Gao SA, Friberg P, Annerstedt M, Carlström J, Ivarsson T, Jensen G, Ljungman S, Mathillas O, Nielsen FD, Strömbom U: Baroreflex effectiveness index and baroreflex sensitivity predict all-cause mortality and sudden death in hypertensive patients with chronic renal failure. J Hypertens 2007, 25:163-168.
• [54]Ritz E, Warnner C: The challege of sudden death in dialysis patients. Clin J Am Soc Nephrol 2008, 3:920-929.
• [55]Drechsler C, Meinitzer A, Pilz S, Krane V, Tomaschitz A, Ritz E, März W, Wanner C: Homoarginine, heart failure, and sudden cardiac death in haemodialysis patients. Eur J Heart Fail 13(8):852-859.
• [56]Drechsler C, Krane V, Ritz E, März W, Wanner C: Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation 2009, 120(24):2421-2428.
• [57]Herzog CA, Asinger RW, Berger AK, Charytan DM, Díez J, Hart RG, Eckardt KU, Kasiske BL, McCullough PA, Passman RS, DeLoach SS, Pun PH, Ritz E: Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011, 80(6):572-586.
• [58]Banach M, Rysz J: Current problems in hypertension and nephrology. Expert Opin Pharmacother 2010, 11(16):2575-2578.
• [59]Bielecka-Dabrowa A, Aronow WS, Rysz J, Banach M: Current place of beta-blockers in the treatment of hypertension. Curr Vasc Pharmacol 2010, 8(6):733-741.
• [60]Chondal M, Goldenberg I, Moss AJ, McNitt S, Cheung AK: Risk factors for sudden cardiac death in patients with chronic renal insufficiency and left ventricular dysfunction. Am J Nephrol 2007, 27(1):7-14.
• [61]Cice G, Ferrara L, D’Andrea A, D’Isa S, Di Benedetto A, Cittadini A, Russo PE, Golino P, Calabrò R: Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 2003, 41:1438-1444.
• [62]Pun PH, Lehrich RW, Smith SR, Middleton JP: Predictors of survival after cardiac arrest in outpatient hemodialysis clinics. Clin J Am Soc Nephrol 2007, 2:491-500.
• [63]Kozlowski D, Budrejko S, Lip GY, Mikhailidis DP, Rysz J, Raczak G, Banach M: Dronedarone: an overview. Ann Med 2012, 44:60-72.
• [64]Fantuzzi S, Caico S, Amatruda O, Cervini P, Abu-Turky H, Baratelli L, Donati D, Gastaldi L: Hemodialysis-associated cardiac arrhythmias: a lower risk with bicarbonate? Nephron 1991, 58(2):196-200.
• [65]Alagiakrishnan K, Banach M, Jones LG, Datta S, Ahmed A, Aronow WS: Update on diastolic heart failure or heart failure with preserved ejection fraction in the older adults. Ann Med 2012.
• [66]Gandhi K, Aronow WS, Desai H, Amin H, Lai HM, Frishman WH, Cohen M, Sorbera C: Incidence of appropriate cardioverter-defibrillator shocks and mortality in patients with implantable cardioverter-defibrillators with ischemic cardiomyopathy versus nonischemic cardiomyopathy at 33-month follow-up. Arch Med Sci 2010, 6:900-903.
• [67]Greenberg H, Case RB, Moss AJ, Brown MW, Carroll ER, Andrews ML, MADIT-II Investigators: Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II). J Am Coll Cardiol 2004, 43(8):1459-1465.
• [68]Zipes DP, Camm AJ, Borggrefe M, American College of Cardiology/American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society, et al.: ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006, 114(10):e385-e484.
• [69]Sredniawa B, Mazurek M, Lenarczyk R, Kowalski O, Kowalczyk J, Kalarus Z: Early therapy following myocardial infarction: arguments for and against implantable cardioverter-defibrillators. Future Cardiol 2010, 6(3):315-323.
• [70]Solomon SD, Zelenkofske S, McMurray JJV, Finn PV, Velazquez E, Ertl G, Harsanyi A, Rouleau JL, Maggioni A, Kober L, White H, Van de Werf F, Pieper K, Califf RM, Pfeffer MA, for the Valsartan in Acute Myocardial Infarction Trial (VALIANT) Investigators: Sudden Death in Patients with Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both. N Engl J Med 2005, 352:2581-2588.
• [71]Piotrowski G, Szymański P, Banach M, Piotrowska A, Gawor R, Rysz J, Gawor Z: Left atrial and left atrial appendage systolic function in patients with post-myocardial distal blocks. Arch Med Sci 2010, 6:892-899.
• [72]Dasgupta A, Montalvo J, Medendorp S, Lloyd-Jones DM, Ghossein C, Goldberger J, Passman R: Increased complication rates of cardiac rhythm management devices in ESRD patients. Am J Kidney Dis 2007, 49:656-663.
• [73]Hreybe H, Ezzeddine R, Bedi M, Barrington W, Bazaz R, Ganz LI, Jain S, Ngwu O, London B, Saba S: Renal insufficiency predicts the time to first appropriate defibrillator shock. Am Heart J 2006, 151:852-856.
• [74]Cuculich P, Sánchez JM, Kerzner R, Greenberg SL, Sengupta J, Chen J, Faddis MN, Gleva MJ, Smith TW, Lindsay BD: Poor prognosis for patients with chronic kidney disease despite ICD therapy for the primary prevention of sudden death. Pacing Clin Electrophysiol 2007, 30:207-213.
• [75]Korantzopoulos P, Liu T, Li L, Goudevenos JA, Li G: Implantable cardioverter defibrillator therapy in chronic kidney disease: a meta-analysis. Europace 2009, 11:1469-1475.
• [76]Herzog CA, Li S, Weinhandl ED, Strief JW, Collins AJ, Gilbertson DT: Survival of dialysis patients after cardiac arrest and the impact of implantable cardioverter defibrillators. Kidney Int 2005, 68(2):818-825.
• [77]Saxon LA, Bristow MR, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, Feldman AM, Galle E, Ecklund F: Predictors of sudden cardiac death and appropariate shock in the comparison of Medical Therapy. Circulation 2006, 114(25):2766-2772.
• [78]Amin MS, Fox AD, Kalahasty G, Shepard RK, Wood MA, Ellenbogen KA: Benefit of primary prevention implantable cardioverter-defibrillators in the setting of chronic kidney disease: a decision model analysis. J Cardiovasc Electrophysiol 2008, 19:1275-1280.
• [79]Meyer P, Desai RV, Mujib M, Feller MA, Adamopoulos C, Banach M, Lainscak M, Aban I, White M, Aronow WS, Deedwania P, Iskandrian AE, Ahmed A: Right ventricular ejection fraction <20% is an independent predictor of mortality but not of hospitalization in older systolic heart failure patients. Int J Cardiol 2012, 155:120-125.
• [80]Sekhri V, Sanal S, DeLorenzo LJ, Aronow WS, Maguire GP: Cardiac sarcoidosis: a comprehensive review. Arch Med Sci 2011, 7:546-554.
• [81]Graff B, Graff G, Koźluk E, Tokarczyk M, Piątkowska A, Budrejko S, Kozłowski D, Dąbrowska-Kugacka A, Lewicka E, Świątecka G, Raczak G: Electrophysiological features in patients with sinus node dysfunction and vasovagal syncope. Arch Med Sci 2011, 7:963-970.
• [82]Nikolić G: Sudden bradycardia. Heart Lung 2011, 40(2):177-179.
• [83]Vardas PE, Auricchio A, Blanc JJ, Daubert JC, Drexler H, Ector H, Gasparini M, Linde C, Morgado FB, Oto A, Sutton R, Trusz-Gluza M, European Society of Cardiology; European Heart Rhythm Association: Guidelines for cardiac pacing and cardiac resynchronization therapy. The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association. Europace 2007, 9(10):959-998.
• [84]Morgan JM: The MADIT II and COMPANION studies: will they affect uptake of device treatment? Heart 2004, 90:243-245.
• [85]Anand IS, Carson P, Galle E, Song R, Boehmer J, Ghali JK, Jaski B, Lindenfeld J, O’Connor C, Steinberg JS, Leigh J, Yong P, Kosorok MR, Feldman AM, DeMets D, Bristow MR: Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: results from the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trial. Circulation. 2009, 119(7):969-977.
• [86]Dickstein K, Vardas PE, Auricchio A, Daubert JC, Linde C, McMurray J, Ponikowski P, Priori SG, Sutton R, van Veldhuisen DJ, Committee for Practice Guidelines of the European Society of Cardiology: 2010 focused update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur J Heart Fail 2010, 12:1143-1153.
• [87]Machnicki G, Lentine KL, Salvalaggio PR, Burroughs TE, Brennan DC, Schnitzler MA: Kidney transplant Medicare payments and length of stay: associations with comorbidities and organ quality. Arch Med Sci 2011, 7:278-286.
• [88]Malyszko J, Malyszko JS, Mikhailidis DP, Rysz J, Zorawski M, Banach M: Hypertension and kidney disease: is renalase a new player or an innocent bystander? J Hypertens 2012, 30:457-462.
• [89]Green D, Green HD, New DI, Kalra PA: The clinical significance of hyperkalaemia-associated repolarization abnormalities in end-stage renal disease. Nephrol Dial Transplant 2012.
• [90]Barylski M, Małyszko J, Rysz J, Myśliwiec M, Banach M: Lipids, blood pressure, kidney - what was new in 2011? Arch Med Sci 2011, 7:1055-1066.
• [91]de Bie MK, Koopman MG, Gaasbeek A, Dekker FW, Maan AC, Swenne CA, Scherptong RW, van Dessel PF, Wilde AA, Schalij MJ, Rabelink TJ, Jukema JW: Incremental prognostic value of an abnormal baseline spatial QRS-T angle in chronic dialysis patients. Europace 2012.